<DOC>
	<DOCNO>NCT00140543</DOCNO>
	<brief_summary>1 . To determine compare efficacy Tacrolimus/Rapa versus Tacrolimus/MMF-based immunosuppression ( conjunction initial short-term steroid polyclonal antibody administration ) Type 1-diabetic patient undergo simultaneous pancreas/kidney allograft transplantation . 2 . To evaluate safety Tacrolimus/Rapa versus Tacrolimus/MMF term drug-related complication overimmunosuppression-associated complication , particularly monitoring pharmacokinetic profile drug administer .</brief_summary>
	<brief_title>European Trial Immunosuppression SPK Tx</brief_title>
	<detailed_description>This control , randomise study , perform 15-20 pancreas transplantation center throughout Europe . Patients randomise one two treatment group . Group 1 receive Tacrolimus Mycophenolate Mofetil ( = best group EuroSPK001 trial ) . Group 2 receive Tacrolimus Sirolimus . Both group receive association short-term corticosteroid polyclonal antibody preparation . Patients randomly assign one 2 treatment group 1:1 ratio transplantation . The study last 3 year , first interim analysis data 6 month complete analysis 1 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient , 18 55 year age , endstage , Cpeptidenegative , Type 1diabetic nephropathy . 2 . Female patient childbearing age must negative pregnancy test must agree maintain effective birth control practice throughout study period ( 3 year ) . 3 . Patient must sign Patient Informed Consent Form . 4 . Patient must receive primary simultaneous pancreas/kidney ( SPK ) cadaveric transplant , either intestinal bladder either portal systemic venous drainage . 1 . Patient pregnant breastfeeding . 2 . Patient allergic intolerant Mycophenolate Mofetil , Sirolimus , Tacrolimus macrolides , compound structurally related compound . 3 . Patient positive Tcell crossmatch recent serum specimen . 4 . Patient know active liver disease significant liver disease , define ASAT ALAT serum level great 3 time upper limit normal . 5 . Patient malignancy history malignancy , exception adequately treat localised squamous cell basal cell carcinoma , without recurrence . 6 . Patient include another clinical trial protocol investigational drug within 4 week prior randomisation . 7 . Patient form substance abuse , psychiatric disorder condition , , opinion investigator , may invalidate communication . 8 . Patient receives SPK transplant live donor , receive segmental pancreatic transplant , previous kidney transplant alone . 9 . Pancreatic duct occlusion technique . 10 . Donor old 55 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>simultaneous pancreas/kidney transplantation</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>